If you are at 2.4 mg weekly (the Wegovy maintenance dose), spend 4 weeks at 1.7 mg, then 4 weeks at 1.0 mg, then 4 weeks at 0.5 mg, then stop
Long-term outlook and what the research shows Retatrutide is still in clinical development, with Phase 3 trials ongoing
Many patients see significant appetite suppression within the first month, leading to earlier weight changes
Several common genetic variants (rs6923761 in GLP1R, rs1800437 in GIPR, rs17782313 in MC4R) correlate with baseline body weight, appetite signaling, and medication response in published cohorts
The peptides are typically administered through injections, with some users taking them daily and others using them once or twice a week
GLP-1 treatments have shown significant effectiveness in weight management and glycemic control, making them popular choices in diabetes care and obesity treatment